Dual-inhibitors of Cellular Necroptosis and Ferroptosis for Use in the Treatment of Organ Transplant Patients

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes new chemical compounds, particularly Nec-1f and related molecules, that can simultaneously inhibit two forms of regulated cell death—necroptosis and ferroptosis. These compounds are intended as medications to help prevent organ transplant rejection and damage, by protecting transplanted organs from cell death that triggers inflammatory immune responses. The key advantage is that a single compound can target both cell death pathways, simplifying treatment for transplant patients and potentially improving transplant outcomes.

Use CasesContent extracted from patent full text and abstract with AI.

• Preventing organ transplant rejection in patients who have received organs such as kidney, liver, heart, or lung transplants.
• Reducing ischemia-reperfusion injury during and after organ transplantation.
• Protecting donor organs during storage and transportation prior to transplantation.
• Treating patients at high risk of acute or chronic transplant dysfunction.
• Reducing necroinflammatory complications following organ or cell transplants.
• Possibly preventing cell death in other clinical settings involving necroptosis and ferroptosis (e.g., ischemic injuries, acute organ injuries, certain neurological diseases).

BenefitsContent extracted from patent full text and abstract with AI.

• Simultaneous inhibition of both necroptosis and ferroptosis with a single compound, unlike current approaches requiring separate drugs.
• Potential to reduce immune system activation and resulting transplant rejection by minimizing release of cellular antigens from dying donor cells.
• Improved survival and function of transplanted organs by reducing cell death and associated damage.
• Reduces the need for complex multi-drug regimens, simplifying regulatory approval and clinical management.
• Flexible administration options (to the donor, organ, or recipient) at various time points to maximize organ protection.
• May reduce long-term complications and improve outcomes for transplant patients.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to chemical compounds for use as a medicament in the prevention of organ transplant rejection and/or transplant organ damage. In embodiments of the invention, the compound inhibits and/or reduces ferroptosis and necroptosis of cells of the transplanted organ. In further embodiments, the patient is at risk of transplant rejection and/or is at risk of or shows signs of ischemia-reperfusion injury and/or necroinflammation.